Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

Vaccine

Volumn 29, Issue 8, 2011, Pages 1677-1682

  Esposito, Susanna ^a   Tagliaferri, Laura ^a   Daleno, Cristina ^a   Valzano, Antonia ^a   Picciolli, Irene ^a   Tel, Francesca ^a   Prunotto, Giulia ^a   Serra, Domenico ^a   Galeone, Carlotta ^a,b   Plebani, Anna ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

A H1N1 influenza vaccine; Adjuvants; HIV; MF59; Pandemic influenza; Pediatrics

Indexed keywords

INFLUENZA VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MALAISE; MALE; PAIN; PRIORITY JOURNAL; RHINITIS; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SKIN INDURATION; SOMNOLENCE; SWELLING; VOMITING;

EID: 79952703778     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.047     Document Type: Article

References (36)

1. Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 1989;261:245.
2. Safrin S, Rush JD, Mills J. Influenza in patients with human immuno deficiency virus infection. Chest 1990;98:33-7.
3. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immuno deficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000;31:604-6.
4. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009;58:1-52.
5. Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009;22:244-9.
6. Kunisaki KM, Janoff EN. Influenza inimmunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
7. Nelson KE, Clements MI, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988;109:383-8.
8. Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, Kimura S, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:167-73.
9. Evison J, Farese S, Seitz M, Uehlinger D, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009;48:1402-12.
10. Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, Pebody RG, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009;339:b5213.
11. Kelly H, Barr I. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 2010;375:6-9.
12. European CDC. ECDC Health Education. On the use of specific pandemic influenza vaccines, 19th August. http://www.ecdc.europa.eu/en/healthtopics/Documents/0908InfluenzaAH1N1Ontheuseofspecificpandemicinfluenzavaccines.pdf; 2009.
13. CDC. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58:1-8.
14. Esposito S, Molteni CG, Colombo C, Daleno C, Daccò V, Lackenby A, et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol 2010;48:62-5.
15. Menegon T, Baldo V, Bonello C, Dalla Costa D, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999;15:573-6.
16. Clerici M, Sarasella M,Colombo F, Fossati S, Sala N, BricalliD, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertically exposure to HIV. Blood 2000;96:3866-71.
17. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-35.
18. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13.
19. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, etal. Immuno-genicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010;303:37-46.
20. Zhu F, Wang H, Fang H, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361: 2414-23.
21. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza AH1N1 vaccines inChina:amul-ticentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375: 56-66.
22. Bickel M, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010;24: F31-5.
23. Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, etal. Immuno-genicity and effect of a virosomal influenza vaccine on viral replication and T cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006;78:440-5.
24. Viganò A, Zuccotti GV, Pacei M, Erba P, Castelletti E, Giacomet V, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-96.
25. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, et al. Influenzavaccineimmunogenicityin6-to23-month-oldchildren:are identical antigens necessary for priming? Pediatrics 2006;118:e570-e578.
26. Mitchell DK, Ruben FL, Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J 2005;10:925-7.
27. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008;15:253-9.
28. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-71.
29. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5.
30. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010;28:4123-9.
31. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010;10:639-51.
32. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-2010 influenza season: a multicentre, randomized controlled trial. Lancet 2010;375:49-55.
33. Radosevic K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 2008;26: 3640-6.
34. Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant; 2010 [Epub October 25].
35. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swiner-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.
36. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52.